{"filing":{"accession_number":"0001193125-26-403356","cik":"0001585608","ticker":"JAGX","company_name":"Jaguar Health, Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-25","primary_document":"d187815d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526403356/d187815d8k.htm"},"events":[{"id":35280,"run_id":32492,"accession_number":"0001193125-26-403356","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"On September 25, 2026, Jaguar Health exchanged 481,584 shares of common stock for a $3.4 million reduction in the outstanding balance of a secured promissory note originally issued in 2021. The shares were issued as unregistered securities under Section 3(a)(9) of the Securities Act, representing a dilutive equity issuance that materially affects the company's capital structure and shareholder equity.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39280,"accession_number":"0001193125-26-403356","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.35,"reasoning":"The filing discloses a debt-for-equity exchange on September 25, 2026, in which Jaguar Health exchanged 481,584 shares of common stock for a $3.4 million reduction in the outstanding balance of a secured promissory note originally issued in 2021. While this involves modification of an existing debt obligation, the core transaction is a dilutive equity issuance in exchange for debt reduction—a capital restructuring event that materially affects the company's capital structure and shareholder equity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:10:01.108173+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39281,"accession_number":"0001193125-26-403356","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 discloses an unregistered sale of equity securities—specifically, \"2021 Note Exchange Shares\" issued under Section 3(a)(9) of the Securities Act. This is a classic dilutive issuance. The incorporation by reference to Item 1.01 suggests this is part of a larger transaction (likely a debt-for-equity exchange or similar capital restructuring). Such unregistered equity issuances are material to investors as they dilute existing shareholders and signal potential financial stress or capital needs.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:10:01.108173+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":35281,"run_id":32492,"accession_number":"0001193125-26-403356","anchor_item_number":"8.01","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"summary":"The filing reports the company's share count as of September 25, 2026, at approximately 1,945,542 shares outstanding.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39282,"accession_number":"0001193125-26-403356","item_number":"8.01","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"This disclosure reports the share count as of September 25, 2026 (approximately 1,945,542 shares outstanding). It is a routine administrative disclosure of capitalization data, typically included for informational purposes in 8-K filings. While share count can be relevant to investors, this bare statement of outstanding shares without context regarding issuances, repurchases, or other capital events is not material on its own and does not signal a governance change or other substantive event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:10:01.108173+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39280,"accession_number":"0001193125-26-403356","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.35,"reasoning":"The filing discloses a debt-for-equity exchange on September 25, 2026, in which Jaguar Health exchanged 481,584 shares of common stock for a $3.4 million reduction in the outstanding balance of a secured promissory note originally issued in 2021. While this involves modification of an existing debt obligation, the core transaction is a dilutive equity issuance in exchange for debt reduction—a capital restructuring event that materially affects the company's capital structure and shareholder equity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:10:01.108173+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-28"},{"id":39281,"accession_number":"0001193125-26-403356","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 3.02 discloses an unregistered sale of equity securities—specifically, \"2021 Note Exchange Shares\" issued under Section 3(a)(9) of the Securities Act. This is a classic dilutive issuance. The incorporation by reference to Item 1.01 suggests this is part of a larger transaction (likely a debt-for-equity exchange or similar capital restructuring). Such unregistered equity issuances are material to investors as they dilute existing shareholders and signal potential financial stress or capital needs.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:10:01.108173+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-28"},{"id":39282,"accession_number":"0001193125-26-403356","item_number":"8.01","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"This disclosure reports the share count as of September 25, 2026 (approximately 1,945,542 shares outstanding). It is a routine administrative disclosure of capitalization data, typically included for informational purposes in 8-K filings. While share count can be relevant to investors, this bare statement of outstanding shares without context regarding issuances, repurchases, or other capital events is not material on its own and does not signal a governance change or other substantive event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:10:01.108173+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-28"}]}